With these premises, we decided to address the influence of ABCB1 and hOCT1 polymorphisms on the response rate and toxicity of first-line nilotinib in the context of a multicenter “real-life” series of 78 CML cases. The gene discussed is ABCB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.